Heart attack patients may benefit from Clot-Busting drug before delayed procedure
NCT ID NCT07641231
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 240 adults having a major heart attack (STEMI) when the standard emergency procedure to open the blocked artery is expected to be delayed by over an hour. Half will get a clot-busting drug (tenecteplase) right away, followed by the procedure within 2-24 hours. The other half will just have the standard procedure. The goal is to see if the early drug reduces the risk of death, stroke, or another heart attack within a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tenecteplase
What this could lead to
If successful, this could show that giving a clot-busting drug early, even when a hospital can do a standard procedure, improves survival and reduces complications after a heart attack.
What could go wrong
This is a Phase 4 study with only 240 participants, so results may not apply to everyone. The clot-busting drug also increases bleeding risk, which could offset any benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI - ST ELEVATION MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Moscow, Select A State, 121552, Russia
Contact Email: •••••@•••••